Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9340959 | Urologic Oncology: Seminars and Original Investigations | 2005 | 8 Pages |
Abstract
Increased serum tumor markers after cisplatin-based chemotherapy have usually been considered a contraindication to surgery because of the presence of persistent active germ cell elements. However, a select population of patients with elevated serum tumor markers have undergone post-chemotherapy retroperitoneal lymph node dissection (RPLND) with curative intent. We evaluated the role of surgery to resect retroperitoneal-only marker positive tumor. Long-term survival was observed in 50% of patients. Residual germ cell cancer was identified in 50% of patients, with a third alive at 5 years with no observed benefit from adjuvant chemotherapy. Select patients with increased tumor markers after chemotherapy are cured with surgery.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Stephen D.W. M.D., Richard S. M.D., Richard M.D., Lawrence H. M.D., John P. M.D.,